Navigation Links
Amorcyte, a NeoStem Company, Enrolls First Patient in PreSERVE Phase 2 Trial for Acute Myocardial Infarction
Date:1/25/2012

NEW YORK, Jan. 25, 2012 /PRNewswire/ -- Amorcyte, LLC, a NeoStem, Inc. company (NYSE Amex: NBS)("NeoStem" or the "Company") today announces the enrollment of the first patient in the Amorcyte PreSERVE Phase 2 trial for acute myocardial infarction. The study is a multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of infarct-related artery infusion of AMR-001, an autologous bone marrow derived cell therapy enriched for CD34+ cells. AMR-001 is administered 5 to 11 days post-stent placement in patients diagnosed with an ST segment elevation myocardial infarction with ejection fraction less than or equal to 48%, as determined by cardiac magnetic resonance imaging measured after recovery from myocardial stunning.  Approximately 160 subjects, age 18 and older, will be randomized 1:1 between the treatment group and control group.  Progenitor Cell Therapy, LLC, also a NeoStem company, will support the manufacturing, product supply, and logistics for the trial.

Dr. Arshed Quyyumi, Professor of Medicine at Emory University and the lead principal investigator in the study said, "We are thrilled to begin evaluating AMR-001, a CD34+ cell therapy, in these patients. We look forward to Phase 2 trial confirmation of the biologic activity of AMR-001 demonstrated in the Phase 1 trial and hope to provide patients with significant clinical benefit and an enriched quality of life."

"The first patient enrollment signals a key advance in our efforts in the trial," said Dr. Andrew L. Pecora, Chief Medical Officer of NeoStem. "We are on track to enroll the targeted 160 patients over the next year or so with first data follow-up six months after the last patient is enrolled."

AMR-001 represents the first compound in this class of cell therapies to have a highly defined cell population and an identified biologically effective therapeutic dose, both of which tie back to the
'/>"/>

SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NeoStem Appoints a Biopharmaceutical Business Leader and a Cellular Therapy Expert to its Board of Directors
2. NeoStem Provides Updates, Reports Results for Third Quarter and Upcoming November Company Presentations
3. NeoStem Announces Change in Presentation Time for JMP Securities Conference
4. NeoStem Announces Participation in Multiple September Conferences
5. NeoStem Appoints Grant Thornton LLP as New Independent Registered Public Accounting Firm
6. NeoStem Provides Update on Amorcyte Clinical Progress and Reports Results for Second Quarter
7. NeoStem Announces Pricing of Public Offering for $16,500,000 in Gross Proceeds
8. NeoStem Announces Proposed Public Offering of Common Stock
9. NeoStem Signs Definitive Merger Agreement to Acquire Amorcyte in Equity Transaction
10. NeoStem Announces Agreement with Nankai Hospital in Tianjin to Offer NeoStems Licensed Orthopedic Technology
11. NeoStems Suzhou Erye Pharmaceutical Receives Two Awards at the Chempharm Brand Summit 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... SEATTLE , Sept. 2, 2014 /PRNewswire/ ... company committed to the development and commercialization ... today announced an update on corporate and ... structure, commitment for future funding, ongoing clinical ... In corporate news, Chief Executive Officer ...
(Date:9/2/2014)... , Sept. 2, 2014  MEI Pharma, Inc. ... focused on the clinical development of novel therapies ... enrollment in a randomized Phase II clinical trial ... combination with azacitidine in patients with previously untreated ... placebo-controlled, double-blind study enrolled a total of 108 ...
(Date:9/2/2014)... Sept. 2, 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ... three drugs in its lipid franchise were highlighted in ... (ESC) Congress in Barcelona Spain . ... designed to provide effective and safe therapeutic options to ... of one commercialized drug and several other drugs in ...
Breaking Medicine Technology:VentiRx Pharmaceuticals Provides Corporate and Clinical Update 2VentiRx Pharmaceuticals Provides Corporate and Clinical Update 3MEI Pharma Completes Enrollment In Randomized Phase II Clinical Trial Of Pracinostat In Front Line Myelodysplastic Syndrome 2MEI Pharma Completes Enrollment In Randomized Phase II Clinical Trial Of Pracinostat In Front Line Myelodysplastic Syndrome 3MEI Pharma Completes Enrollment In Randomized Phase II Clinical Trial Of Pracinostat In Front Line Myelodysplastic Syndrome 4Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014 2Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014 3Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014 4Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014 5
... CHICAGO, May 25, 2012  Dallas entrepreneur Clayton Redmon has ... Black Enterprise . (Photo: http://photos.prnewswire.com/prnh/20120525/DA13928 ) ... StreamVenue Healthcare , was among three ... Business Awards, People,s Choice Award presented at the ...
... PARSIPPANY, N.J., May 25, 2012  Watson Pharmaceuticals, Inc. (NYSE: ... company, announced today that Siggi Olafsson, Watson,s President of ... the Company,s business at the Jefferies 2012 Global Healthcare ... Time at the Grand Hyatt in New York, New ...
Cached Medicine Technology:StreamVenue Healthcare CEO Named People's Choice Winner 2Watson to Present at the Jefferies 2012 Global Healthcare Conference 2
(Date:9/2/2014)... News) -- The quality of Americans, diets has improved ... the rich and poor is growing, a new study ... to date that the extensive efforts by many groups ... some payoff, but it also indicates that these efforts ... doctoral student in the department of nutrition at the ...
(Date:9/2/2014)... Amy Norton HealthDay Reporter , ... want to lose weight and boost their heart health, cutting ... a new study suggests. In a small clinical trial ... a low-carbohydrate diet lost more weight over a year than ... bigger improvements in their cholesterol and triglyceride levels, the research ...
(Date:9/2/2014)... Philadelphia, PA (PRWEB) September 02, 2014 ... Magee Rehabilitation Hospital returns on September 19 at The ... Hill, Pennsylvania. Over the past 25 years, the Classic, ... more than $12 million for programs and services designed ... at Magee Rehabilitation Hospital. , “The Segal Classic ...
(Date:9/2/2014)... 02, 2014 North America Resectoscopes ... Market Outlook to 2020? provides key market data ... provides value, in millions of US dollars, volume ... within market segments –,     Rigid ... Reusable) Electrodes and Bipolar (Disposable and Reusable) Electrodes). ...
(Date:9/2/2014)... 02, 2014 Humility of Mary Health Partners ... at St. Elizabeth Health Center, 1044 Belmont Ave. , The ... more than 200 common health problems as well as tips ... injury, and advice on when to seek medical attention. ... in the Youngstown Room; the evening session runs from 5:30 ...
Breaking Medicine News(10 mins):Health News:Quality of U.S. Diet Improves, Slightly 2Health News:Low-Carb Beats Low-Fat for Weight Loss, Heart Health: Study 2Health News:Low-Carb Beats Low-Fat for Weight Loss, Heart Health: Study 3Health News:The 25th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 3Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 4Health News:HMHP Offers ‘Health at Home’ Workshop 2
... of the Johns Hopkins Children,s Center and Scott Sicherer of ... caution when ordering allergy tests and to avoid making a ... article, published in the January issue of Pediatrics , ... tool in recent years, and skin-prick testing, an older weapon ...
... Doheny HealthDay Reporter , FRIDAY, Dec. 23 (HealthDay ... imaging tests between diagnosis and surgery than they did in ... -- breast ultrasounds, MRIs and mammograms -- help doctors determine ... hassles and expense of care, the study says. ...
... News) -- Reindeer have lots to do this time of ... sleighs -- but despite all their frenzied activity they manage ... overheated, researchers have found. Now, Norwegian scientists have gained ... of reindeer as they exercised on solid ground. In ...
... 23 (HealthDay News) -- Obese people who have had surgery to ... of the disease or die from cancer within five years as ... the study, published in the Dec. 1 issue of the ... Rochester, Minn., suggested their findings could change the way some doctors ...
... FRIDAY, Dec. 23 (HealthDay News) -- The holiday season can ... take steps to ensure they stay healthy through this often ... is a cancer survivor and their ranks are growing. Many ... disease and its treatment, experts at the Fred Hutchinson ...
... , FRIDAY, Dec. 23 (HealthDay News) -- Parents of ... lifestyle changes that will benefits their kids, health, a ... efforts to combat the childhood obesity epidemic among Hispanic ... United States, said the researchers at University of Texas ...
Cached Medicine News:Health News:Memo to pediatricians: Allergy tests are no magic bullets for diagnosis 2Health News:Memo to pediatricians: Allergy tests are no magic bullets for diagnosis 3Health News:Breast Cancer Patients Face More Imaging Tests Today 2Health News:Breast Cancer Patients Face More Imaging Tests Today 3Health News:Study Shows How Busy Reindeer Keep Their Cool 2Health News:Obesity Linked to Higher Esophageal Cancer Death Rates 2Health News:Cancer Survivors Should Take Steps to Keep Healthy During Holidays 2Health News:Parents May Hold Key to Healthy Weight in Hispanic Kids 2
... diagnostic capabilities combined with ease of use ... in its class. Ideal for office or ... system for Uroflowmetry, cystometry, leak point pressure, ... are available which make the OM-5 flexible ...
The Duet EnCompass Pelvic Floor Diagnostic System is the only equipment specifically designed to perform urodynamics, anorectal manometry, EMG and pudendal nerve latency studies on a single software ...
... The Corkscrew FT II (fully threaded) is ... designed to be inserted flush with the ... and anchor stability. The full thread design ... anchors with protruding eyelets. Especially advantageous when ...
... Corkscrew Parachute Tissue Anchor allows one step fixation ... ideal for arthroscopic knotless rotator cuff repair in ... has an outside thread diameter of 5 mm ... #2 FiberWire suspension sutures securely hold a thin, ...
Medicine Products: